Darunavir/cobicistat/emtricitabine/tenofovir alafenamide

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide is a combination drug used in the treatment of HIV/AIDS. It combines four antiretroviral medications in one: darunavir, cobicistat, emtricitabine, and tenofovir alafenamide, each with a distinct mechanism of action against the Human Immunodeficiency Virus (HIV). This combination is designed to inhibit the virus's ability to replicate in the body, thereby reducing the viral load and increasing the number of CD4+ T cells. The use of a combination therapy approach is a cornerstone in the management of HIV, as it reduces the risk of drug resistance development.

Composition

The medication is a fixed-dose combination of the following drugs:

• Darunavir: A protease inhibitor that prevents HIV from maturing into its infectious form.
• Cobicistat: A pharmacokinetic enhancer that increases the effectiveness of darunavir by inhibiting the enzyme that metabolizes it, allowing for higher concentrations of darunavir in the blood.
• Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that interferes with the HIV virus's ability to make copies of itself.
• Tenofovir alafenamide: A prodrug of tenofovir, another NRTI, which is converted into its active form inside the body, providing effective levels of the drug with lower doses compared to its predecessor, tenofovir disoproxil fumarate, thus reducing potential kidney and bone toxicity.

Indications

This combination is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. It is used as part of antiretroviral therapy for patients with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of the drug.

Administration

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide is taken orally, once daily, with food. The presence of food enhances the absorption of darunavir and cobicistat, making it more effective.

Side Effects

Common side effects include, but are not limited to, diarrhea, nausea, fatigue, headache, and rash. Serious side effects may include liver problems, kidney problems, and a buildup of lactic acid in the blood (lactic acidosis), which can be fatal. Patients should be monitored for the development of side effects, and any new symptoms should be reported to a healthcare provider immediately.

Drug Interactions

This medication should not be used in conjunction with other drugs that strongly affect the enzyme CYP3A, as this can alter the effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential drug interactions.

Conclusion

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide represents a significant advancement in the treatment of HIV/AIDS, offering patients a highly effective, once-daily regimen that can improve adherence and outcomes. However, like all medications, it comes with potential side effects and interactions that need to be managed under the guidance of a healthcare provider.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian